Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation.

"the data were downloaded from supporting information data files ( https://www omicsdi org/dataset/geo/gse118133 ) reported in reference ."

"CONFLICT OF INTEREST Dr Speel reports personal fees from Amgen, Eli Lilly and Novartis, outside the submitted work. Nonfinancial support from Biocartis and Abbvie and grants from AstraZeneca, Pfizer, Novartis and Bayer, outside the submitted work. Dr Dingemans reports financial conflicts (ad board, paid to institute) of Eli Lilly, Roche, Amgen, Jansen, Pfizer, Astra‐Zeneca, Bayer, Boehringer, Ingelheim, Sanofi, outside the submitted work. Dr van Engeland is co‐founder and shareholder of Epify BV and MLA Diagnostics BV, companies which develop cancer DNA methylation markers. All other authors declare no potential conflicts of interest. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization."

"Funding Information This work was supported by the Dutch Cancer Foundation [grant number 10956, 2017 to Ernst‐Jan M. Speel], the French National Cancer Institute (INCa, PRT‐K‐17‐047 to Lynnette Fernandez‐Cuesta and Matthieu Foll), the Ligue Nationale Contre le Cancer (LNCC 2016 to Lynnette Fernandez‐Cuesta), and the NeuroendocrineTumor Research Foundation (NETRF, Investigator Award 2019 to Lynnette Fernandez‐Cuesta). Lise Mangiante has a fellowship from the LNCC. The results shown here are in part based upon data generated by the TCGA Research Network ( https://www.cancer.gov/tcga ) and the Rare Cancers Genomics initiative ( http://rarecancersgenomics.com/lungnenomics/ )."